Memory Disorders Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major memory disorders markets are expected to exhibit a CAGR of 5.42% during 2024-2034.
The memory disorders market has been comprehensively analyzed in IMARC's new report titled "Memory Disorders Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Memory disorders refer to a group of conditions characterized by significant impairments in memory function and other cognitive abilities. These diseases can affect a person's capability to acquire, retain, or recall information, leading to difficulties in daily functioning and a decline in overall neural performance. Some common symptoms associated with the illness include confusion, disorientation, feeling lost, engaging in repetitive actions, frequently misplacing objects, impaired judgment and decision-making, inability to recognize familiar people, etc. This ailment can also lead to changes in mood, personality, and behavior, such as increased irritability, anxiety, depression, or withdrawal from social activities. The diagnosis of memory disorders typically involves a comprehensive evaluation of the patient's medical history, clinical features, and physical workup. A healthcare provider may further conduct brain imaging techniques, like MRI or PET scans, to identify any structural abnormalities or signs of neurodegeneration. Various other investigations, including the Mini-Mental State Examination (MMSE), the Montreal Cognitive Assessment (MoCA), the clock-drawing test, etc., are also utilized to determine the thinking abilities of an individual suffering from the disease.
The increasing cases of neurodegenerative syndromes, which affect cognitive functions due to the progressive deterioration of brain cells and neural networks, are primarily driving the memory disorders market. In addition to this, the rising prevalence of numerous associated risk factors, including chronic alcoholism, drug abuse, infections, stroke, severe head injuries, older age, genetic mutations, etc., is also creating a positive outlook for the market. Moreover, the widespread adoption of cognitive stimulation therapy that focuses on stimulating and engaging the patient's neural abilities as well as promoting social interaction, is further bolstering the market growth. Apart from this, the inflating application of effective medications, such as cholinesterase inhibitors, antidepressants, memantine, etc., owing to their various advantages, like slowing down the disease progression, improving mood and behavior, and enhancing the quality of life, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of monoclonal antibodies, which are designed to target and reduce the accumulation of beta-amyloid plaques in the brain, thereby boosting cognitive outcomes, is expected to drive the memory disorders market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the memory disorders market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for memory disorders and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the memory disorders market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the memory disorders market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the memory disorders market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current memory disorders marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the memory disorders market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the memory disorders market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the memory disorders market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of memory disorders across the seven major markets?
What is the number of prevalent cases (2018-2034) of memory disorders by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of memory disorders by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with memory disorders across the seven major markets?
What is the size of the memory disorders patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of memory disorders?
What will be the growth rate of patients across the seven major markets?
Memory Disorders: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for memory disorders drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the memory disorders market?
What are the key regulatory events related to the memory disorders market?
What is the structure of clinical trial landscape by status related to the memory disorders market?
What is the structure of clinical trial landscape by phase related to the memory disorders market?
What is the structure of clinical trial landscape by route of administration related to the memory disorders market?
The memory disorders market has been comprehensively analyzed in IMARC's new report titled "Memory Disorders Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Memory disorders refer to a group of conditions characterized by significant impairments in memory function and other cognitive abilities. These diseases can affect a person's capability to acquire, retain, or recall information, leading to difficulties in daily functioning and a decline in overall neural performance. Some common symptoms associated with the illness include confusion, disorientation, feeling lost, engaging in repetitive actions, frequently misplacing objects, impaired judgment and decision-making, inability to recognize familiar people, etc. This ailment can also lead to changes in mood, personality, and behavior, such as increased irritability, anxiety, depression, or withdrawal from social activities. The diagnosis of memory disorders typically involves a comprehensive evaluation of the patient's medical history, clinical features, and physical workup. A healthcare provider may further conduct brain imaging techniques, like MRI or PET scans, to identify any structural abnormalities or signs of neurodegeneration. Various other investigations, including the Mini-Mental State Examination (MMSE), the Montreal Cognitive Assessment (MoCA), the clock-drawing test, etc., are also utilized to determine the thinking abilities of an individual suffering from the disease.
The increasing cases of neurodegenerative syndromes, which affect cognitive functions due to the progressive deterioration of brain cells and neural networks, are primarily driving the memory disorders market. In addition to this, the rising prevalence of numerous associated risk factors, including chronic alcoholism, drug abuse, infections, stroke, severe head injuries, older age, genetic mutations, etc., is also creating a positive outlook for the market. Moreover, the widespread adoption of cognitive stimulation therapy that focuses on stimulating and engaging the patient's neural abilities as well as promoting social interaction, is further bolstering the market growth. Apart from this, the inflating application of effective medications, such as cholinesterase inhibitors, antidepressants, memantine, etc., owing to their various advantages, like slowing down the disease progression, improving mood and behavior, and enhancing the quality of life, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of monoclonal antibodies, which are designed to target and reduce the accumulation of beta-amyloid plaques in the brain, thereby boosting cognitive outcomes, is expected to drive the memory disorders market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the memory disorders market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for memory disorders and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the memory disorders market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the memory disorders market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the memory disorders market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current memory disorders marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the memory disorders market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the memory disorders market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the memory disorders market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of memory disorders across the seven major markets?
What is the number of prevalent cases (2018-2034) of memory disorders by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of memory disorders by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with memory disorders across the seven major markets?
What is the size of the memory disorders patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of memory disorders?
What will be the growth rate of patients across the seven major markets?
Memory Disorders: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for memory disorders drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the memory disorders market?
What are the key regulatory events related to the memory disorders market?
What is the structure of clinical trial landscape by status related to the memory disorders market?
What is the structure of clinical trial landscape by phase related to the memory disorders market?
What is the structure of clinical trial landscape by route of administration related to the memory disorders market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 MEMORY DISORDERS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 MEMORY DISORDERS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 MEMORY DISORDERS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 MEMORY DISORDERS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 MEMORY DISORDERS - UNMET NEEDS
10 MEMORY DISORDERS - KEY ENDPOINTS OF TREATMENT
11 MEMORY DISORDERS - MARKETED PRODUCTS
11.1 List of Memory Disorders Marketed Drugs Across the Top 7 Markets
11.1.1 Aduhelm (Aducanumab) - Biogen/Eisai Co Ltd/Neurimmune Therapeutics
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Namenda (Memantine) - Merz Pharma
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Razadyne (Galantamine) - Janssen/Sanochemia Pharmazeutika
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Leqembi (Lecanemab) - BioArctic/Eisai
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Namzaric (Donepezil/memantine extended release) - Adamas Pharmaceuticals
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 MEMORY DISORDERS - PIPELINE DRUGS
12.1 List of Memory Disorders Pipeline Drugs Across the Top 7 Markets
12.1.1 Donanemab - Eli Lilly and Company
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Masitinib - AB Science
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 BAC - Charsire Biotechnology Corporation
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 AGB 101 - AgeneBio
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 DNL593 - Denali Therapeutics Inc
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. MEMORY DISORDERS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. MEMORY DISORDERS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 MEMORY DISORDERS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Memory Disorders - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Memory Disorders - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Memory Disorders - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Memory Disorders - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Memory Disorders - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Memory Disorders - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Memory Disorders - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Memory Disorders - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Memory Disorders - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Memory Disorders - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Memory Disorders - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Memory Disorders - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Memory Disorders - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Memory Disorders - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Memory Disorders - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Memory Disorders - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Memory Disorders - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Memory Disorders - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Memory Disorders - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Memory Disorders - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Memory Disorders - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Memory Disorders - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Memory Disorders - Access and Reimbursement Overview
16 MEMORY DISORDERS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 MEMORY DISORDERS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 MEMORY DISORDERS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 MEMORY DISORDERS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 MEMORY DISORDERS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 MEMORY DISORDERS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 MEMORY DISORDERS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 MEMORY DISORDERS - UNMET NEEDS
10 MEMORY DISORDERS - KEY ENDPOINTS OF TREATMENT
11 MEMORY DISORDERS - MARKETED PRODUCTS
11.1 List of Memory Disorders Marketed Drugs Across the Top 7 Markets
11.1.1 Aduhelm (Aducanumab) - Biogen/Eisai Co Ltd/Neurimmune Therapeutics
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Namenda (Memantine) - Merz Pharma
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Razadyne (Galantamine) - Janssen/Sanochemia Pharmazeutika
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Leqembi (Lecanemab) - BioArctic/Eisai
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Namzaric (Donepezil/memantine extended release) - Adamas Pharmaceuticals
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 MEMORY DISORDERS - PIPELINE DRUGS
12.1 List of Memory Disorders Pipeline Drugs Across the Top 7 Markets
12.1.1 Donanemab - Eli Lilly and Company
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Masitinib - AB Science
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 BAC - Charsire Biotechnology Corporation
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 AGB 101 - AgeneBio
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 DNL593 - Denali Therapeutics Inc
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. MEMORY DISORDERS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. MEMORY DISORDERS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 MEMORY DISORDERS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Memory Disorders - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Memory Disorders - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Memory Disorders - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Memory Disorders - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Memory Disorders - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Memory Disorders - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Memory Disorders - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Memory Disorders - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Memory Disorders - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Memory Disorders - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Memory Disorders - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Memory Disorders - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Memory Disorders - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Memory Disorders - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Memory Disorders - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Memory Disorders - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Memory Disorders - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Memory Disorders - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Memory Disorders - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Memory Disorders - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Memory Disorders - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Memory Disorders - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Memory Disorders - Access and Reimbursement Overview
16 MEMORY DISORDERS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 MEMORY DISORDERS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 MEMORY DISORDERS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
